As of 2025-10-26, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -16.68. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 10,372.88 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -622.03 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 13.7x | 13.4x |
| Forward P/E multiples | 14.1x - 16.9x | 15.8x |
| Fair Price | (45.88) - (44.71) | (47.51) |
| Upside | -184.6% - -182.4% | -187.6% |
| Date | EV/EBITDA |